PROS1 and COVID-19: Despite the success of global COVID-19 immunization programs resulting in protection against severe COVID-19, widely employed vaccines based on the ancestral S protein provide only short-lived protection against mild to moderate disease and have low vaccine effectiveness against symptomatic disease with Omicron [27,28].